Riax
3
Medicina | 5.4MB
Descrizione
Dr.Reddy’s Laboratories Ltd. (NYSE:RDY) and AstraZeneca Pharma India Limited (AZPIL)(BSE : 506820, NSE : ASTRAZEN, AZPIL) today announced that they have entered into a distribution agreement for Riax®, a new brand of saxagliptin and Riax-M a fixed dose combination of saxagliptin with metformin. Both Riax® and Riax M are trademarks of the AstraZeneca group. AZPIL already has two brands under the trademark Onglyza® and Kombiglyze® for saxagliptin and in fixed dose combination with metformin respectively, promoted and distributed in the Indian market.
Show More
Less
Informazione
Aggiornata: 2015-11-08
Versione corrente: 1.4
È necessario Android: Android 3.0 or later